Loading the state's markets…
Loading the state's markets…
Loading the market…
Medicare market size, surgeons and outlook to 2030
Medicare fee-for-service structural heart (TAVR, TEER) cases in New Hampshire: reported (2020, the pandemic year, left out of the line), then forecast with its 80% range. One year ahead, this procedure’s market forecast has been off by 4% on average (219 state-years, 2020–2024): a close guide.
| Year | Surgeons | Medicare FFS | Advantage share |
|---|---|---|---|
| 2019 | 17 | 421 | 21% |
| 2020 | 19 | 460 | 25% |
| 2021 | 20 | 540 |
Transcatheter aortic valve replacement and mitral edge-to-edge repair. Professional codes (what the surgeon bills): CPT 33361, 33362, 33363, 33364, 33365, 33366, 33418, 33419; the hospital bills MS-DRG 266, 267.
Surgeons and fee-for-service cases are from CMS’s Medicare Physician & Other Practitioners files, counted where the surgeon billed; state totals include the cases CMS leaves out of the surgeon-level file (under 11 patients). All Medicare adds patients in Medicare Advantage at the state’s enrollment share; all payers scales Medicare by its share of the procedure nationally. The forecast carries cases per resident 65+ forward with the Census projection of residents 65+. How the numbers are made · Data sources
The 10 busiest do 67% of the cases CMS names in New Hampshire; 14 surgeons do 80% of them.
MedaRep names every one, ranked by volume, with their practice, hospitals, trend, forecast and which device companies already engage with them.
| State | Surgeons | Medicare FFS | Growth since 2019 | Per 1,000 | Out of hospital | Forecast |
|---|---|---|---|---|---|---|
| New York | 150 | 4,552+1.5%/yr | +1.5%/yr | 2.1 | 0% | 6,000 in 2030+4.7%/yr |
| Pennsylvania | 158 |
| Surgeons | Medicare FFS | Growth since 2019 | Per 1,000 | Out of hospital | Forecast | |
|---|---|---|---|---|---|---|
| Coronary intervention (PCI) | 25 | 1,180−3.6%/yr | −3.6%/yr | 4.50.9× | 0% | 1,640 in 2030+5.7%/yr |
| Mechanical circulatory support |
Structural heart (TAVR, TEER) in every state, and its device makers · Every procedure market in New Hampshire · Every state · Compare with New York
| ≈ 790 |
| – |
| 2026 est. | ≈ 920 | – |
| 29% |
| 2022 | 22 | 563 | 33% |
| 2023 | 21 | 662 | 37% |
| 2024 | 24 | 582 | 39% |
| 2025 from claims | – | 787 636–924 | 40% |
| 2026 forecast | – | 916 717–1,150 | 35% |
| 2027 forecast | – | 1,006 746–1,330 | 34% |
| 2028 forecast | – | 1,106 783–1,527 | 34% |
| 2029 forecast | – | 1,216 826–1,743 | 33% |
| 2030 forecast | – | 1,336 875–1,983 | 33% |
In 2025, 100% inpatient hospital.
| 2,820+2.5%/yr |
| +2.5%/yr |
| 1.7 |
| 0% |
| 3,580 in 2030+4%/yr |
| Massachusetts | 66 | 2,037+3.4%/yr | +3.4%/yr | 1.9 | 0% | 3,210 in 2030+7.9%/yr |
| New Jersey | 71 | 1,653+2.7%/yr | +2.7%/yr | 1.4 | 0% | 2,140 in 2030+4.4%/yr |
| Connecticut | 32 | 563−1.1%/yr | −1.1%/yr | 1.4 | 0% | 1,000 in 2030+10%/yr |
| Rhode Island | 9 | 263+10%/yr | +10%/yr | 2.3 | 0% | 340 in 2030+4.3%/yr |
| Maine | 15 | 221+2.2%/yr | +2.2%/yr | 1.1 | 0% | 460 in 2030+13%/yr |
| Vermont | 6 | 189+4.2%/yr | +4.2%/yr | 1.5 | 0% | 300 in 2030+7.8%/yr |
| 2 |
| 133+3.3%/yr |
| +3.3%/yr |
| 0.61.0× |
| 0% |
| 120 in 2030−1.2%/yr |
Share of the cases CMS names by surgeon, by where they billed. Open one for its ranking.
Edwards Lifesciences leads with 50% of company spending on these surgeons in 2025, +25 pts on 2024.
In 2025, 4 companies reported engagement with New Hampshire’s surgeons worth $128K in consulting, speaking, meals and travel tied to these products, about $5,352 per surgeon billing it. Royalties are left out.
FDA, last 12 months: 52 clearances and approvals in the category, 3 recalled product lines. A recall is a public FDA notice, not a finding of fault.
Which surgeons each company engages, and the dollars reported, are in the ranking. Open Payments shows the payments companies reported. It suggests engagement, not which devices a surgeon uses, and is not evidence of wrongdoing. Every company in the category.